Randomized phase III trial of amrubicin versus topotecan (Topo) as second-line treatment for small cell lung cancer (SCLC).

作者：Robert M. Jotte, Joachim von Pawel, David Robert Spigel, Mark A. Socinski, M. E. R. O’Brien, Eugene Paschold, Jörg Michael Mezger, Martin B. Steins, Lionel Bosquée, Jeffrey Alan Bubis, Kris L. Nackaerts, Jimena Pérez, P. Clingan, Wolfgang Schuette, Paul C. Lorigan, Martin Reck, Manuel Dómine, Frances Alice Shepherd, Richard McNally, Markus Frederic Renschler · 发表于：Journal of Clinical Oncology · 年份：2011 · DOI：10.1200/jco.2011.29.15_suppl.7000 · 被引用次数：49 · 研究领域：Lung Cancer Research Studies、Pancreatic and Hepatic Oncology Research、Cancer therapeutics and mechanisms

7000